Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211
Almost every alpha cancer therapy in development relies on one scarce isotope. Developing several alternatives at once would stop the whole field waiting on a single supply chain.
Overview
Actinium-225 dominates targeted alpha therapy pipelines, but lead-212 (from thorium-228/radium-224 generators, used by Orano Med and Perspective Therapeutics), astatine-211 (cyclotron-produced, short half-life, suited to regional supply) and terbium-149 have complementary properties and independent supply routes. The proposal is a public-private programme that funds isotope-agnostic chelator and linker chemistry, comparative dosimetry and small head-to-head clinical studies so that a given targeting ligand can be paired with whichever alpha emitter is available, and that de-risks generator and cyclotron capacity for each.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Similar pages
not linked directly; found by shared links- TechnologyMacropa chelation
Shares Radium-224, Bismuth-213, Lead-212, Targeted alpha therapy.
- IdeaRegional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit
Shares Actinium-225 supply, Alpha vs beta emitters, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.
- CompanyAdvanCell
Shares Radium-224, Lead-212, Targeted alpha therapy, Actinium-225.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Orano Med, Actinium-225 supply, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.
- IdeaPretargeted alpha radioimmunotherapy
Shares Bismuth-213, Astatine-211, Targeted alpha therapy, Actinium-225.
- TechnologyAlpha-emitter daughter redistribution ('free daughter' problem)
Shares Bismuth-213, Lead-212, Targeted alpha therapy, Actinium-225.
- InstitutionQST Hospital (National Institutes for Quantum Science and Technology)
Shares Astatine-211, Alpha vs beta emitters, Targeted alpha therapy.
- TechnologyAlpha-emitter nanogenerators and daughter trapping
Shares Perspective Therapeutics, Alpha vs beta emitters, Targeted alpha therapy, Actinium-225.